CF PharmTech (02652) has signed a placing agreement with CLSA Limited, CCB International Capital, SkyVast Securities and Somerley Capital to issue 21.75 million new H shares at HK$13.82 each. The offer price represents an 11.97% discount to the last closing price of HK$15.70 on 30 July 2026 and a 12.15% discount to the five-day average of HK$15.732.

The new shares correspond to 7.23% of the company’s existing H-share capital and 5.30% of total issued shares. Post-placement, H shares will rise to 323.97 million, lifting the public float from 56.7% to 58.9% while keeping substantial shareholders below disclosure thresholds.

Gross proceeds are expected at HK$300.55 million; after placement commissions and expenses, net proceeds are estimated at HK$294.81 million, implying a net issue price of HK$13.56 per share. The issuance will be executed under the company’s existing general mandate, of which 36.15% will be utilised, leaving capacity to issue a further 38.42 million H shares.

Allocation of net proceeds: • 70% (HK$206.37 million) – Clinical and pre-clinical development of innovative inhalation drug candidates, including ICF004 (IPF/PPF), ICF001 (PAH/PH-ILD) and four additional early-stage programmes. • 15% (HK$44.22 million) – Global development of complex inhalation formulations such as CF048, CF059/60, CF066 EDS, CF067, CF068 and CF011/88. • 15% (HK$44.22 million) – Working capital and general corporate purposes.

Full deployment of the funds is targeted by 31 December 2029. The company notes that these proceeds are incremental to the HK$525.40 million raised at IPO in October 2025, of which HK$396.20 million remained unspent as of 30 June 2026.

Completion of the placement is conditional on Stock Exchange listing approval and other customary conditions. Settlement is scheduled for 6 August 2026. The company has agreed to a 90-day lock-up on further equity issuance, excluding shares issued under employee award schemes.